Predict Radiographic Damage with 14-3-3η and CRP
14-3-3η, a clinically proven biomarker for earlier, more accurate RA diagnosis, prognosis and monitoring, is available as a stand alone test at Quest Diagnostics and Labcorp
14-3-3n blood test: Uncouple Joint Damage & Inflammation
- High-14-3-3η & CRP levels significantly increase the relative risk for Rapid Erosive Progression (REP), whether antibodies are positive or not
- Add 14-3-3η to routine CRP to assist with RA tight treatment control strategies, since together the two markers increase prediction of rapid radiographic progression
- Patients with a low CRP and high 14-3-3η levels have a double likelihood of flaring than those with a low 14-3-3η level, marking response to treatment as a complement to CRP
